© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Biological activities of fibroblast growth factor-2 in the adult myocardium
aDepartment of Physiology, University of Manitoba, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 3J7
bDepartment of Anatomy, University of Manitoba, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 3J7
* Corresponding author. Tel.: +1-204-789-3735; fax: +1-204-789-3934. peter_cattini{at}umanitoba.ca
Fibroblast growth factor-2 (FGF-2) is a potent regulator of many cellular functions and phenomena, including cell proliferation, differentiation, survival, adhesion, migration, motility and apoptosis, and processes such as limb formation, wound healing, tumorigenesis, angiogenesis, vasculogenesis and blood vessel remodeling. In the adult myocardium, FGF-2 is expressed by various cell types, including cardiomyocytes, fibroblasts and smooth muscle cells. The biological effects of FGF-2 in the myocardium are mediated by the high-affinity tyrosine kinase receptor FGFR-1, the major FGF receptor in the heart. Here, we give an overview of current insights into the multiple roles of FGF-2 in the myocardium, as they pertain to two basic phenomena: ischemia–reperfusion injury and cardiac hypertrophy. The first category includes roles for FGF-2 in cardioprotection, the inflammatory response, angiogenesis and vascular remodeling, while the second includes myocyte hypertrophy, fibrosis, and gap junction functioning (conduction). Given the strong evidence for FGF-2 as both a cardioprotective and angiogenic agent, the therapeutic potential of FGF-2 in the ischemic myocardium is discussed.
KEYWORDS Angiogenesis; Growth factors; Hypertrophy; Ischemia; Signal transduction
1 Present address: School of Medicine, University of California–San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0613, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. J. Hausenloy and D. M. Yellon Cardioprotective growth factors Cardiovasc Res, July 15, 2009; 83(2): 179 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Lavine and D. M. Ornitz Shared Circuitry: Developmental Signaling Cascades Regulate Both Embryonic and Adult Coronary Vasculature Circ. Res., January 30, 2009; 104(2): 159 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okada, T. R. Payne, B. Zheng, H. Oshima, N. Momoi, K. Tobita, B. B. Keller, J. A. Phillippi, B. Peault, and J. Huard Myogenic Endothelial Cells Purified From Human Skeletal Muscle Improve Cardiac Function After Transplantation Into Infarcted Myocardium J. Am. Coll. Cardiol., December 2, 2008; 52(23): 1869 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mizukami, K. Ono, C.-K. Du, T. Aki, N. Hatano, Y. Okamoto, Y. Ikeda, H. Ito, K. Hamano, and S. Morimoto Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion Cardiovasc Res, September 1, 2008; 79(4): 589 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Y. Lu, D. P. Sontag, K. A. Detillieux, and P. A. Cattini FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1242 - C1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Boodhwani, P. Voisine, M. Ruel, N. R. Sodha, J. Feng, S.-H. Xu, C. Bianchi, and F. W. Sellke Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 645 - 650. [Abstract] [Full Text] [PDF]
|
|